Comparison of serum levels of calcium and magnesium among preeclamptic and normotensive pregnant women at Nnamdi Azikiwe University Teaching Hospital, Nnewi, Nigeria

Background:Despite numerous studies, the exact aetiology of pre-eclampsia remains unknown. Some studies have shown that supplementation of calcium and magnesium could ameliorate the effects of pre-eclampsia. The objective of this study was to compare the calcium and magnesium levels in the serum of Nigerian women with or without pre-eclampsia.Methods:In this study, serum calcium and magnesium levels were determined using atomic absorption spectrometry in 54 patients and 48 healthy normotensive pregnant women. The mean, standard deviation, Student’s‘t’ test and Pearson correlation were employed.Results:Serum calcium was significantly lower in patients than controls (9.17 ± 0.6 vs. 7.22 ± 0.5 mg/dl. P <0.001) (t test). Plasma Magnesium was significantly lower in patients than controls 13.19 ± 1.1 vs. 9.81 ± 0.7 mg/dl. P <0.001). The systolic and diastolic blood pressure showed significant inverse correlation with both calcium and magnesium (P<0.01).Conclusion:There was significant reduction in the levels of calcium and magnesium in patients with pre-eclampsia. Dietary supplementation of these trace elements may help to prevent pre-eclampsia

Efficacy of zinc supplementation for the treatment of dysmenorrhoea: a double-blind randomised controlled trial

Objectives To determine the efficacy of zinc sulfate supplementation in managing dysmenorrhoea. Methods In total, 103 high school students were randomised into an experimental arm (52 students) and a control arm (51 students) and received 40-mg zinc sulfate or placebo, respectively, over three cycles. Primary outcome measures were the mean Visual Analogue Scale score, which measured pain over three cycles, and the frequency of nausea and vomiting. Secondary outcomes were the use of additional analgesics and the frequency of allergic reactions. Results Fifty participants were analysed in each group. Mean pain scores were not significantly different between the groups before administering zinc sulfate therapy. Following the intervention, the mean pain scores for the treatment (2.80 ± 2.28) and placebo (3.48 ± 2.85) groups were not significantly different in the first cycle; however, scores in the treatment group were significantly better in the second (2.56 ± 1.97 vs 3.80 ± 2.77) and third (1.95 ± 1.72 vs 3.95 ± 2.82) cycles. No significant differences were observed between the groups in the nausea and vomiting incidence and the requirement for additional analgesics. Conclusions Zinc sulfate reduces dysmenorrhoea severity with minimal or no adverse effects, especially with more than one cycle of usage. Trial Registration Number: PACTR202105843292338. The trial is publicly available and was registered at www.pactr.org on 25 May 2021